20.500.12556/DiRROS-28094 CCR5 Δ32 and CTLA-4 +49 A/G gene polymorphisms and interferon-β treatment response in Croatian and Slovenian multiple sclerosis patients The aim of the present study was to investigate the impact of CCR5 Δ32 and CTLA-4 polymorphisms on the response to IFN-β treatment in our cohort of MS patients from Croatia and Slovenia. Genomic DNA was obtained from 295 MS patients (230 female; 65 male) classified as responders (n = 173) and non-responders (n = 122) based on clinical criteria for treatment efficacy. Genotyping was performed via PCR/PCR-RFLP. No significant differences in the genotype/allele frequencies of CCR5Δ32 and CTLA-4 +49 A/G were detected between male responders and nonresponders. A significantly higher prevalence (p = 0.039) of the CTLA-4 +49 AA genotype was found in female responders (42.1%) compared to non-responders (28.9%). Using multiple forward regression analysis, the CTLA-4 +49 AA genotype significantly predicted a positive response to IFN-β therapy in females (p = 0.011) and contributed to 4.5% of response variability. Furthermore, the combined presence of the CCR5Δ32 wtwt/CTLA-4 +49 AA genotype significantly predicted a positive response to treatment in females (p = 0.025). The age at disease onset, pretreatment relapse rate, and baseline EDSS score were not reliable predictors of treatment response in MS patients. Our results indicate that the presence of the CCR5Δ32 polymorphism was not associated with the response to IFN-β treatment, whereas the CTLA-4 +49 polymorphism showed a positive correlation with an optimal response in female patients. multiple sclerosis polymorphism treatment response interferon-β true false true Angleški jezik Ni določen Neznano 2026-03-10 09:21:14 2026-03-10 09:21:14 2026-03-11 03:59:12 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 19. 6. 2025; str. 1-11 iss. 13, [article no.] 7412 Vol. 25 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.8 1422-0067 10.3390/ijms25137412 239992835 RAZ_Nekic_Jasna_2024.pdf RAZ_Nekic_Jasna_2024.pdf 1 6EEF687C14AC351D146B8D5DCBEC461A 613048393241f2d5855c201c18e644d0e963cca401d6d1ebe0bc2db249a88318 3922caf1-1c5a-11f1-acf8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41511 https://doi.org/10.3390/ijms25137412 0 452b1872-1c5a-11f1-acf8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41512 Univerzitetni klinični center Ljubljana 0 0 0